Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Short, Long, Late Side Effects of Autologous Stem Cell Transplant for Multiple Myeloma

Share Button

Hematopoietic stem cell transplantation (ASCT) is aggressive therapy for multiple myeloma patients and can bring serious short, long-term and late stage collateral damage aka side effects.

I was diagnosed with multiple myeloma (MM) in early 1994 and underwent a hematopoietic stem cell transplant (ASCT) in December of 1995. The years following my ASCT have been filled with short, long-term and late stage side effects caused by my ASCT. While an autologous stem cell transplant has a place in the treatment of multiple myeloma, painful experience has taught me that this aggressive, toxic therapy can damage the patient’s brain, heart, endocrine system, eyes, just about all his/her organs.

Your oncologist probably won’t explain to you all of the life alterning side effects of ASCT. In short, an ASCT should not be used until it is absolutely necessary.

More importantly, it is an open question if the advancements of modern MM therapy has eliminated the need for stem cell transplantation. In other words, if newly diagnosed MM patients can achieve minimal residual disease (negative) status, an ASCT might not result in longer overall survival on average.

Have you been diagnosed with multiple myeloma? Has your oncologist recommended an ASCT? What was your stage and symptoms at diagnosis? What are your goals?

Scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up

“However, hematopoietic stem cell transplantation (HSCT) survivors are at risk of developing long-term complications, such as

  • endocrinopathies,
  • musculoskeletal disorders,
  • cardiopulmonary compromise and
  • subsequent malignancies.

These complications have a direct impact on the morbidity and mortality experienced by HSCT survivors. Two-thirds of HSCT survivors develop at least one chronic health condition; while a fifth develop severe or life-threatening conditions.

HSCT patients who have survived for at least 5 years post-transplantation are at a fourfold to ninefold increased risk of late mortality for as long as 30 years from HSCT, producing an estimated 30% lower life expectancy compared with the general population…”

Quality of life and mood predicts post-traumatic stress disorder after hematopoietic stem cell transplantation

“In this study, we demonstrate that a significant proportion of patients undergoing HCT report PTSD and depression symptoms at six months post-HCT, further illustrating the substantial psychological burden endured by this population…”

Endocrine disorders during the first year after autologous stem-cell transplant.

“In this prospective study we investigated early (at 3 months) and late (at 12 months) endocrine dysfunctions in 95 consecutive autologous stem-cell transplant recipients (47 men and 48 women) aged 16 to 55 years. The functions of the hypothalamic-pituitary-gonadal/thyroid/adrenal/somatotroph axis were evaluated…

This study documents frequent endocrine disorders during the first year after autologous stem-cell transplant. Despite a tendency to improve, in more than half of the cases, the complications persisted for more than 1 year. Therefore, to diagnose and correct early and late endocrine dysfunctions, endocrine screening is required during the first year in all patients undergoing autografting.”

Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.

” Patients who have undergone HDT and AHSCT are at significant risk for developing a second malignancy and should receive indefinite follow-up…”

Leave a Comment:

3 comments
Add Your Reply